Stem Cell Therapy for ALS / Motor Neurone Disease in 2026
An honest, evidence-based look at how mesenchymal stem cell therapy is being used for ALS — what the science supports, what realistic expectations are, and how to think clearly through difficult choices.
Understanding ALS in 2026
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND), is a progressive neurodegenerative condition in which motor neurons in the brain and spinal cord progressively die, leading to muscle weakness, atrophy, and eventually paralysis. Median survival from diagnosis remains around 3-5 years, although significant variation exists. Approximately 450,000 people worldwide live with ALS at any given time.
Conventional treatment in 2026 has improved modestly. Riluzole and edaravone provide small but measurable benefits in survival and functional decline. Sodium phenylbutyrate-taurursodiol (Relyvrio) was approved and then withdrawn following negative confirmatory trials. Tofersen has been approved for the small subset of patients with SOD1 gene mutations. Multidisciplinary clinical care with respiratory, nutritional, physiotherapy, speech, and palliative support significantly improves quality of life and survival. But there is no cure, and most patients face progressive decline despite optimal care.
Stem cell therapy has been intensely researched in ALS for over two decades. The biological rationale is strong: MSCs offer anti-inflammatory, neuroprotective, and growth-factor-secreting effects relevant to the multiple pathological mechanisms in ALS. However, despite many trials, no stem cell therapy has yet shown definitive disease-modifying benefit in large Phase 3 studies. This guide presents the honest 2026 picture.
An Honest Conversation Before You Read Further
ALS is one of the most aggressive areas of medical-tourism marketing, and unfortunately many of the loudest claims about stem cell therapy for ALS are not supported by evidence. We want to be transparent before any patient or family considers travelling for treatment.
What the evidence supports: MSC therapy may modestly slow functional decline in some patients with ALS, particularly when delivered early and intrathecally to the central nervous system. The Israeli BrainStorm NurOwn programme has produced the most rigorous Phase 2/3 data, with a Phase 3 trial that did not meet its primary endpoint but showed signals of benefit in earlier-stage patients. Several other groups have published encouraging Phase 1/2 data.
What the evidence does not support: Any clinic claiming that stem cell therapy will reverse established ALS, restore lost motor function, or cure the disease is making claims that go beyond available evidence. We encourage every patient and family to weigh the financial, logistical, and emotional cost of treatment against realistic, evidence-based expectations. The right decision is highly individual and should be made with the involvement of your neurologist and family.
How MSCs Could Help in ALS
Multiple pathological mechanisms in ALS provide plausible targets for MSC intervention.
Neuroinflammation Reduction
Activated microglia and astrocytes contribute to motor neuron damage in ALS. MSCs powerfully reduce neuroinflammation through paracrine signalling.
Neurotrophic Support
MSCs secrete neurotrophic factors (GDNF, BDNF, VEGF) that may support struggling motor neurons and slow their degeneration.
Glutamate Excitotoxicity
MSCs may modulate the glutamate excitotoxicity that contributes to motor neuron death, complementing the mechanism of riluzole.
Oxidative Stress
Mitochondrial dysfunction and oxidative stress drive ALS pathology. MSCs and their exosomes provide partial protection through multiple antioxidant mechanisms.
Astrocyte Function
Dysfunctional astrocytes contribute to motor neuron toxicity. MSCs help restore healthier glial support of remaining motor neurons.
Functional Stabilisation
When effective, the clinical signal is generally slowed rate of decline in measures like ALSFRS-R rather than dramatic improvement in lost function.
What the Clinical Evidence Actually Shows
The most rigorous clinical evidence for stem cell therapy in ALS comes from BrainStorm Cell Therapeutics' NurOwn programme — autologous MSCs engineered to secrete higher levels of neurotrophic factors. The Phase 3 trial published in 2022 did not meet its primary endpoint but showed benefit signals in early-stage patients. Multiple other Phase 1/2 trials of various MSC protocols (autologous bone marrow, allogeneic Wharton's jelly, intrathecal versus IV delivery) have shown encouraging safety and biomarker signals but have not yet produced definitive Phase 3 evidence of disease modification.
The most consistent findings across MSC studies in ALS have been: acceptable safety profile, particularly with intrathecal delivery; modest slowing of functional decline in some patients, more often in earlier-stage disease; and improvements in inflammatory biomarkers in cerebrospinal fluid. The treatment effect, when present, is incremental rather than transformative.
In 2026, the honest summary is that MSC therapy for ALS is biologically plausible and supported by preliminary clinical data, but is not a proven disease-modifying treatment. Patients considering treatment should approach it as a possibly-helpful adjunct with realistic expectations, not as a treatment that will cure or reverse the disease.
Treatment Protocol
Effective ALS protocols typically prioritise intrathecal delivery — direct injection of MSCs into the cerebrospinal fluid via lumbar puncture — to provide cells direct access to the central nervous system. Most protocols combine intrathecal injection with intravenous infusion to address both CNS and systemic inflammation. Cell doses are individualised, with intrathecal doses typically in the range of 50-100 million cells and IV doses of 100-200 million cells.
Most ALS patients receive 2-3 infusions over a 5-7 day stay, with consideration of repeat treatment every 3-6 months for as long as the patient remains stable enough to tolerate the protocol and continues to derive benefit. The intrathecal procedure is performed in a hospital setting under specialist supervision; the IV infusions are outpatient. Most patients require coordination of respiratory and mobility support during their stay.
Pre-treatment evaluation includes detailed neurological assessment (ALSFRS-R, respiratory function, swallowing, cognitive screening), imaging review, and detailed family discussion about goals and realistic expectations. We do not encourage patients with very advanced disease, severe respiratory compromise, or short expected survival to travel for treatment when the burden likely outweighs the realistic potential benefit.
Integration with Conventional ALS Care
MSC therapy is intended to complement, not replace, evidence-based multidisciplinary ALS care.
Continue Standard Care
Riluzole, edaravone, and any other prescribed medications should be continued. MSC therapy is adjunctive, not a replacement.
Multidisciplinary Team
Your existing ALS multidisciplinary team — neurologist, respiratory therapist, physiotherapist, speech, dietitian — should remain central to your care.
Respiratory Management
Non-invasive ventilation, BiPAP, and other respiratory support should be optimised before considering travel for treatment.
Nutritional Support
Adequate nutrition is essential. PEG feeding tubes should be established if needed before international travel rather than during it.
Quality of Life Focus
Treatment decisions should incorporate quality-of-life impact, not just functional measures. Travel and treatment burden matter.
Family Involvement
ALS treatment decisions are family decisions. We encourage open discussion of goals, expectations, and the family's capacity to support travel and treatment.
Suitability Considerations
ALS treatment selection requires particularly careful consideration of risk, benefit, and burden.
Frequently Asked Questions
Coordinamento Internazionale dei Pazienti
StemCell Longevita opera come piattaforma di coordinamento internazionale dei pazienti. Mettiamo in contatto i pazienti con istituzioni mediche autorizzate che offrono applicazioni di medicina rigenerativa dopo valutazione medica e nel rispetto dei quadri normativi applicabili. Tutte le decisioni e le procedure mediche sono condotte esclusivamente da professionisti sanitari autorizzati. StemCell Longevita non fornisce direttamente trattamenti medici.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Stem cell therapy is an evolving field, and outcomes may vary by individual. The treatments described on this site have not been fully evaluated or approved by the FDA or equivalent regulatory bodies in all jurisdictions.
The FDA has not approved stem cell applications for most conditions listed on this website. Results mentioned are based on clinical observations, published research, and patient-reported outcomes. Individual results may vary and no specific outcomes are assured for any individual patient.
L'inclusione di pubblicazioni scientifiche su questo sito non implica approvazione normativa o risultati clinici garantiti. Alcune applicazioni possono essere considerate sperimentali a seconda dell'indicazione e della giurisdizione.
Always consult with a qualified healthcare professional before making any medical decisions. Do not disregard professional medical advice or delay seeking treatment based on information found on this website.